GI Stromal Tumors: 15 Years of Lessons From a Rare Cancer

Angela Cioffi; Robert G Maki

doi:10.1200/JCO.2014.59.7344

GI Stromal Tumors: 15 Years of Lessons From a Rare Cancer

J Clin Oncol. 2015 Jun 1;33(16):1849-54. doi: 10.1200/JCO.2014.59.7344. Epub 2015 Apr 27.

Authors

Angela Cioffi¹, Robert G Maki²

Affiliations

¹ All authors: Tisch Cancer Institute, Mount Sinai Medical Center, New York, NY.
² All authors: Tisch Cancer Institute, Mount Sinai Medical Center, New York, NY. bobmakimd@gmail.com.

PMID: 25918303
DOI: 10.1200/JCO.2014.59.7344

Abstract

A confluence of factors, most prominently the recognition of GI stromal tumor (GIST) as a specific sarcoma subtype and the availability of imatinib, led to the "Big Bang" of GIST therapy (ie, the successful treatment of the first patient with GIST with imatinib in 2000). The trail blazed by imatinib for chronic myelogenous leukemia and GIST has become a desired route to regulatory approval of an increasing number of oral kinase inhibitors and other novel therapeutics. In this review, the status of GIST management before and after GIST's "Big Bang" and new steps being taken to further improve on therapy are reviewed.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Antineoplastic Agents / therapeutic use*
Biomarkers, Tumor / genetics
Biomarkers, Tumor / metabolism
Chemotherapy, Adjuvant
Diagnostic Imaging
Digestive System Surgical Procedures
Gastrointestinal Stromal Tumors / drug therapy*
Gastrointestinal Stromal Tumors / enzymology
Gastrointestinal Stromal Tumors / genetics
Gastrointestinal Stromal Tumors / mortality
Gastrointestinal Stromal Tumors / pathology
Humans
Molecular Targeted Therapy*
Neoplasm Staging
Protein Kinase Inhibitors / therapeutic use*
Signal Transduction / drug effects
Treatment Outcome

Substances

Antineoplastic Agents
Biomarkers, Tumor
Protein Kinase Inhibitors